Research is an important component of the work performed by the Memory Disorders Clinic at the University of North Carolina Chapel Hill. In addition to providing important clinical care to the North Carolina community, the Memory Disorders Clinic coordinates a number of research studies investigating memory disorders, with a particular focus on non-Alzheimer’s dementias. Listed below are some ongoing studies:

NC Registry for Brain Health

The NC Registry for Brain Health is a mailing list of people who are interested in learning about ongoing research studies in North Carolina that are designed to improve brain health and prevent conditions such as Alzheimer’s disease (AD).

Contact:  Johanna Silbersack, (919) 843-3085


ARTFL – Advancing Research and Treatment for Frontotemporal Lobar Degeneration

Frontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes: frontotemporal dementia (FTD), primary progressive aphasia (PPA), corticobasal degeneration syndrome (CBS) and progressive supranuclear palsy syndrome (PSPS). The goal of this study is to build a FTLD clinical research consortium to support the development of FTLD therapies for new clinical trials.

Contact: Jessica Ferrall, (919) 962-8852


DLBC – Dementia with Lewy Bodies Consortium

The purpose of this study is to collect clinical information, brain imaging scans, and biological samples from people that have dementia with Lewy bodies. This information will help researchers gain a better understanding of the biology behind LBD.

Contact: Jessica Ferrall, (919) 962-8852


ACP-103-046: A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Safety Study of Pimavanserin Therapy in Adult and Elderly Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease.

The purpose of this study is to assess the safety and tolerability of pimavanserin compared to placebo in adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease.

Contact: Carlos Velez, (919) 962-5137


ACP-103-047: A 52-Week Open-Label Extension Study of Pimavanserin in Adult and Elderly Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease

The purpose of this study is to evaluate the long-term safety and tolerability of pimavanserin in adult and elderly subjects with neuropsychiatric symptoms related to neurodegenerative disease exposed to open-label pimavanserin for up to 52 weeks.

Contact: Carlos Velez, (919) 962-5137


ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration

Contact: Carlos Velez, (919) 962-5137